Aravind Subramanian

Head of Digital & Technology Platforms at Dewpoint Therapeutics

Prior to Dewpoint, Aravind trained at the Broad Institute of MIT and Harvard where he held roles of increasing responsibility, most recently as Director, Computational R&D.

Aravind’s research at the Broad Institute focused on technologies for generating large-scale perturbational datasets and their computational analysis. Over the past decade, Aravind’s team has generated several large perturbation datasets by treating cultured human cells with small-molecule and biological agents. These data, coupled with powerful pattern recognition algorithms, are made available in a popular public resource called the Connectivity Map and are routinely used by drug hunters to understand mechanisms of action of small-molecules, functionally annotate disease genes, and inform clinical studies.


Org chart

No direct reports

Teams

This person is not in any teams


Offices

This person is not in any offices


Dewpoint Therapeutics

Dewpoint Therapeutics is the first company founded to apply the emerging discipline of biomolecular condensates to drug discovery. Dewpoint believes that a vast range of conditions has pathways that are regulated by condensates or arise from the dysfunction of condensates - including cancer, neurodegeneration, and metabolic disease.


Employees

51-200

Links